Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine vs AraC-Based Consolidation Before allo-HSCT in High-Risk Adult AML
ChiCTR2500112777Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax, azacitidine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: 2-year leukemia free survival. Started Nov 2025; status: recruiting.
02
Drugs
venetoclaxazacitidinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500112777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112777.